$0.32
arrow_drop_down16.66%Performance History
| Key Stats | |
|---|---|
| Open | $0.35 |
| Prev. Close | $0.39 |
| EPS | -1.83 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| Market Cap | 17844450.00 |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 0.31 | 0.36 |
| 52 Week Range | 0.21 | 1.09 |
| Ratios | |
|---|---|
| P/B Ratio | 0.22 |
| Revenue | $2.56M |
| Operating M. % | -5,044.55% |
| Earnings | $0.00 |
| Earnings Growth % | -43.26% |
| EBITDA Margin % | -1,000.00% |
| ROEÂ % | -96.97% |
| EPS | -1.83 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Analyst Forecast
Period: Next 12 Months
•Analyst Ratings
Correlated Companies
About Senti Biosciences (SNTI)
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Timothy K. Lu M.D., Ph.D.
- Headquarters
- South San Francisco
- Employees
- 122
- Exchange
- NASDAQ
Keep an eye on Senti Biosciences
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
What is Senti Biosciences's (SNTI) price per share?
The current price per share for Senti Biosciences (SNTI) is $0.32. The stock has seen a price change of -$0.06 recently, indicating a -16.67% change. This reflects the stock's recent market performance and investor sentiment.
What is the 52-week high and low for Senti Biosciences (SNTI)?
For Senti Biosciences (SNTI), the 52-week high is $1.09, which is 235.38% from the current price. The 52-week low is $0.21, the current price is 54.03% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
Is Senti Biosciences (SNTI) a growth stock?
Senti Biosciences (SNTI) has shown an average price growth of 0.41% over the past three years. It has received a score of -5 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Senti Biosciences as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
What is Senti Biosciences (SNTI) stock price performance year to date (YTD)?
As of the latest data, Senti Biosciences (SNTI) has a year-to-date price change of -50.83%. Over the past month, the stock has experienced a price change of 8.48%. Over the last three months, the change has been -6.88%. Over the past six months, the figure is -50.83%.
Is Senti Biosciences (SNTI) a profitable company?
Senti Biosciences (SNTI) has a net income of -$83.41M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -5.04K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $2.56M, although specific revenue growth data is currently not available. Operating income is noted at -$66.76M. Furthermore, the EBITDA is -$60.24M.
What is the market capitalization of Senti Biosciences (SNTI)?
Senti Biosciences (SNTI) has a market capitalization of $17.84M. The average daily trading volume is 44.76M, indicating the stock's liquidity and investor engagement.
News
Actions for Diversifying Your Penny Stocks Portfolio in 2024
Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy
Penny Stock Traders Guide to Different Order Types
Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights
Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)
Sign up for our newsletter
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.